Back

Press Releases

  1. Press Releases

Press Releases

Press Releases

October 20, 2020
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Oct. 20, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical
October 20, 2020
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Oct. 20, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical
September 23, 2020
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Sept. 23, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG) (“CENTOGENE” or the “Company”), a commercial-stage company focused on rare diseases that transforms real- world clinical and genetic data into actionable information for patients,
September 23, 2020
CENTOGENE expands its SARS-CoV-2 testing solution to Düsseldorf Airport after successfully launching walk-in COVID-19 test facilities at Frankfurt and Hamburg Airport Company’s PCR tests now available for passengers departing from or arriving at Düsseldorf Airport, as well as to the general public
September 10, 2020
CENTOGENE has opened an expanded sampling area, next to the existing Walk-In COVID-19 Testing Facility, allowing significant increases in COVID-19 testing sampling capacity Innovative digital solutions continue to support the fight against the novel coronavirus with a customer-friendly testing
August 20, 2020
CAMBRIDGE, Mass. and ROSTOCK, Germany and HAMBURG, Germany and BERLIN, Aug. 20, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and
August 19, 2020
CENTOGENE expands its SARS-CoV-2 testing solution to Hamburg Airport after successfully launching the first walk-in COVID-19 test facility at Frankfurt Airport in June 2020 in cooperation with Lufthansa Company’s PCR tests now available for passengers departing from Hamburg, and returning to
August 11, 2020
CAMBRIDGE, Mass., and ROSTOCK and BERLIN, Aug. 11, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies,
August 4, 2020
CENTOGENE expands ongoing development cooperation with Ministry of Health and Social Protection of the Population of Tajikistan (MoH) to now include COVID-19 testing The project supports access to testing materials and laboratory devices for SARS-CoV-2 testing – funded by the German Federal
June 23, 2020
Cambridge, Mass. and ROSTOCK, Germany and BERLIN, June 23, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical
May 15, 2020
CAMBRIDGE, Mass. and BERLIN and ROSTOCK, Germany, May 15, 2020 (GLOBE NEWSWIRE) -- Centogene N.V (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical
May 5, 2020
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN,, May 05, 2020 (GLOBE NEWSWIRE) -- CENTOGENE (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies,
April 16, 2020
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, April 16, 2020 (GLOBE NEWSWIRE) -- CENTOGENE (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies,
April 15, 2020
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Germany, April 15, 2020 (GLOBE NEWSWIRE) -- CENTOGENE (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical
March 18, 2020
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Germany, March 18, 2020 (GLOBE NEWSWIRE) -- CENTOGENE (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians and pharmaceutical
March 17, 2020
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, March 17, 2020 (GLOBE NEWSWIRE) -- CENTOGENE N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical
March 9, 2020
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, March 09, 2020 (GLOBE NEWSWIRE) -- CENTOGENE (Nasdaq: CNTG) ─ The Company today announced that Dr. Dirk H. Ehlers, COO and President of its Clinical Diagnostics Division, has decided to step down from his role after the Annual General Meeting in
February 29, 2020
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Feb. 29, 2020 (GLOBE NEWSWIRE) -- CENTOGENE (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians and pharmaceutical companies,